This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fogg, C.
Right arrow Articles by Moss, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fogg, C.
Right arrow Articles by Moss, B.

 Previous Article  |  Next Article 

Journal of Virology, October 2004, p. 10230-10237, Vol. 78, No. 19
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.19.10230-10237.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions

Christiana Fogg,1 Shlomo Lustig,1,{dagger} J. Charles Whitbeck,2 Roselyn J. Eisenberg,2 Gary H. Cohen,2 and Bernard Moss1*

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland,1 Schools of Dental and Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania2

Received 29 April 2004/ Accepted 24 May 2004

Infectious intracellular and extracellular forms of vaccinia virus have different outer membrane proteins, presenting multiple targets to the immune system. We investigated the immunogenicity of soluble forms of L1, an outer membrane protein of the intracellular mature virus, and of A33 and B5, outer membrane proteins of the extracellular enveloped virus. The recombinant proteins, in 10-µg amounts mixed with a Ribi- or saponin-type adjuvant, were administered subcutaneously to mice. Antibody titers to each protein rose sharply after the first and second boosts, reaching levels that surpassed those induced by percutaneous immunization with live vaccinia virus. Immunoglobulin G1 (IgG1) antibody predominated after the protein immunizations, indicative of a T-helper cell type 2 response, whereas live vaccinia virus induced mainly IgG2a, indicative of a T-helper cell type 1 response. Mice immunized with any one of the recombinant proteins survived an intranasal challenge with 5 times the 50% lethal dose of the pathogenic WR strain of vaccinia virus. Measurements of weight loss indicated that the A33 immunization most effectively prevented disease. The superiority of protein combinations was demonstrated when the challenge virus dose was increased 20-fold. The best protection was obtained with a vaccine made by combining recombinant proteins of the outer membranes of intracellular and extracellular virus. Indeed, mice immunized with A33 plus B5 plus L1 or with A33 plus L1 were better protected than mice immunized with live vaccinia virus. Three immunizations with the three-protein combination were necessary and sufficient for complete protection. These studies suggest the feasibility of a multiprotein smallpox vaccine.

* Corresponding author. Mailing address: 4 Center Dr., MSC 0445, NIH, Bethesda, MD 20892-0445. Phone: (301) 496-9869. Fax: (301) 480-1147. E-mail: bmoss{at}nih.gov.

{dagger} Present address: Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.

Journal of Virology, October 2004, p. 10230-10237, Vol. 78, No. 19
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.19.10230-10237.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Benhnia, M. R.-E.-I., McCausland, M. M., Laudenslager, J., Granger, S. W., Rickert, S., Koriazova, L., Tahara, T., Kubo, R. T., Kato, S., Crotty, S. (2009). Heavily Isotype-Dependent Protective Activities of Human Antibodies against Vaccinia Virus Extracellular Virion Antigen B5. J. Virol. 83: 12355-12367 [Abstract] [Full Text]  
  • Meseda, C. A., Mayer, A. E., Kumar, A., Garcia, A. D., Campbell, J., Listrani, P., Manischewitz, J., King, L. R., Golding, H., Merchlinsky, M., Weir, J. P. (2009). Comparative Evaluation of the Immune Responses and Protection Engendered by LC16m8 and Dryvax Smallpox Vaccines in a Mouse Model. CVI 16: 1261-1271 [Abstract] [Full Text]  
  • Kennedy, R., Pankratz, V. S., Swanson, E., Watson, D., Golding, H., Poland, G. A. (2009). Statistical Approach To Estimate Vaccinia-Specific Neutralizing Antibody Titers Using a High-Throughput Assay. CVI 16: 1105-1112 [Abstract] [Full Text]  
  • Benhnia, M. R.-E.-I., McCausland, M. M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koriazova, L., Kubo, R., Kato, S., Crotty, S. (2009). Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement. J. Virol. 83: 1201-1215 [Abstract] [Full Text]  
  • Midgley, C. M., Putz, M. M., Weber, J. N., Smith, G. L. (2008). Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J. Gen. Virol. 89: 2992-2997 [Abstract] [Full Text]  
  • Fogg, C. N., Americo, J. L., Earl, P. L., Resch, W., Aldaz-Carroll, L., Eisenberg, R. J., Cohen, G. H., Moss, B. (2008). Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge. J. Virol. 82: 8022-8029 [Abstract] [Full Text]  
  • Kaufman, D. R., Goudsmit, J., Holterman, L., Ewald, B. A., Denholtz, M., Devoy, C., Giri, A., Grandpre, L. E., Heraud, J.-M., Franchini, G., Seaman, M. S., Havenga, M. J. E., Barouch, D. H. (2008). Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice. J. Virol. 82: 6829-6837 [Abstract] [Full Text]  
  • Xu, R.-H., Cohen, M., Tang, Y., Lazear, E., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H., Sigal, L. J. (2008). The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. JEM 205: 981-992 [Abstract] [Full Text]  
  • Berhanu, A., Wilson, R. L., Kirkwood-Watts, D. L., King, D. S., Warren, T. K., Lund, S. A., Brown, L. L., Krupkin, A. K., VanderMay, E., Weimers, W., Honeychurch, K. M., Grosenbach, D. W., Jones, K. F., Hruby, D. E. (2008). Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge. J. Virol. 82: 3517-3529 [Abstract] [Full Text]  
  • Benhnia, M. R.-E.-I., McCausland, M. M., Su, H.-P., Singh, K., Hoffmann, J., Davies, D. H., Felgner, P. L., Head, S., Sette, A., Garboczi, D. N., Crotty, S. (2008). Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine. J. Virol. 82: 3751-3768 [Abstract] [Full Text]  
  • Bielinska, A. U., Chepurnov, A. A., Landers, J. J., Janczak, K. W., Chepurnova, T. S., Luker, G. D., Baker, J. R. Jr. (2008). A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine. CVI 15: 348-358 [Abstract] [Full Text]  
  • Chen, Z., Earl, P., Americo, J., Damon, I., Smith, S. K., Yu, F., Sebrell, A., Emerson, S., Cohen, G., Eisenberg, R. J., Gorshkova, I., Schuck, P., Satterfield, W., Moss, B., Purcell, R. (2007). Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model. J. Virol. 81: 8989-8995 [Abstract] [Full Text]  
  • Perera, L. P., Waldmann, T. A., Mosca, J. D., Baldwin, N., Berzofsky, J. A., Oh, S.-K. (2007). Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice. J. Virol. 81: 8774-8783 [Abstract] [Full Text]  
  • Harland, D. N., Chu, K., Haque, A., Nelson, M., Walker, N. J., Sarkar-Tyson, M., Atkins, T. P., Moore, B., Brown, K. A., Bancroft, G., Titball, R. W., Atkins, H. S. (2007). Identification of a LolC Homologue in Burkholderia pseudomallei, a Novel Protective Antigen for Melioidosis. Infect. Immun. 75: 4173-4180 [Abstract] [Full Text]  
  • Aldaz-Carroll, L., Xiao, Y., Whitbeck, J. C., de Leon, M. P., Lou, H., Kim, M., Yu, J., Reinherz, E. L., Isaacs, S. N., Eisenberg, R. J., Cohen, G. H. (2007). Major Neutralizing Sites on Vaccinia Virus Glycoprotein B5 Are Exposed Differently on Variola Virus Ortholog B6. J. Virol. 81: 8131-8139 [Abstract] [Full Text]  
  • Garcia, A. D., Meseda, C. A., Mayer, A. E., Kumar, A., Merchlinsky, M., Weir, J. P. (2007). Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines. CVI 14: 1032-1044 [Abstract] [Full Text]  
  • Jing, L., Chong, T. M., Byrd, B., McClurkan, C. L., Huang, J., Story, B. T., Dunkley, K. M., Aldaz-Carroll, L., Eisenberg, R. J., Cohen, G. H., Kwok, W. W., Sette, A., Koelle, D. M. (2007). Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus. J. Immunol. 178: 6374-6386 [Abstract] [Full Text]  
  • Golovkin, M., Spitsin, S., Andrianov, V., Smirnov, Y., Xiao, Y., Pogrebnyak, N., Markley, K., Brodzik, R., Gleba, Y., Isaacs, S. N., Koprowski, H. (2007). Smallpox subunit vaccine produced in planta confers protection in mice. Proc. Natl. Acad. Sci. USA 104: 6864-6869 [Abstract] [Full Text]  
  • Tang, J., Murtadha, M., Schnell, M., Eisenlohr, L. C., Hooper, J., Flomenberg, P. (2006). Human T-cell responses to vaccinia virus envelope proteins.. J. Virol. 80: 10010-10020 [Abstract] [Full Text]  
  • Heraud, J.-M., Edghill-Smith, Y., Ayala, V., Kalisz, I., Parrino, J., Kalyanaraman, V. S., Manischewitz, J., King, L. R., Hryniewicz, A., Trindade, C. J., Hassett, M., Tsai, W.-P., Venzon, D., Nalca, A., Vaccari, M., Silvera, P., Bray, M., Graham, B. S., Golding, H., Hooper, J. W., Franchini, G. (2006). Subunit Recombinant Vaccine Protects against Monkeypox. J. Immunol. 177: 2552-2564 [Abstract] [Full Text]  
  • Jacobs, N., Chen, R. A.-J., Gubser, C., Najarro, P., Smith, G. L. (2006). Intradermal immune response after infection with Vaccinia virus.. J. Gen. Virol. 87: 1157-1161 [Abstract] [Full Text]  
  • Law, M., Carter, G. C., Roberts, K. L., Hollinshead, M., Smith, G. L. (2006). From the Cover: Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. USA 103: 5989-5994 [Abstract] [Full Text]  
  • Chen, Z., Earl, P., Americo, J., Damon, I., Smith, S. K., Zhou, Y.-H., Yu, F., Sebrell, A., Emerson, S., Cohen, G., Eisenberg, R. J., Svitel, J., Schuck, P., Satterfield, W., Moss, B., Purcell, R. (2006). Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA 103: 1882-1887 [Abstract] [Full Text]  
  • Putz, M. M., Alberini, I., Midgley, C. M., Manini, I., Montomoli, E., Smith, G. L. (2005). Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J. Gen. Virol. 86: 2955-2960 [Abstract] [Full Text]  
  • Lustig, S., Fogg, C., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H., Moss, B. (2005). Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge. J. Virol. 79: 13454-13462 [Abstract] [Full Text]  
  • Davies, D. H., McCausland, M. M., Valdez, C., Huynh, D., Hernandez, J. E., Mu, Y., Hirst, S., Villarreal, L., Felgner, P. L., Crotty, S. (2005). Vaccinia Virus H3L Envelope Protein Is a Major Target of Neutralizing Antibodies in Humans and Elicits Protection against Lethal Challenge in Mice. J. Virol. 79: 11724-11733 [Abstract] [Full Text]  
  • Morikawa, S., Sakiyama, T., Hasegawa, H., Saijo, M., Maeda, A., Kurane, I., Maeno, G., Kimura, J., Hirama, C., Yoshida, T., Asahi-Ozaki, Y., Sata, T., Kurata, T., Kojima, A. (2005). An Attenuated LC16m8 Smallpox Vaccine: Analysis of Full-Genome Sequence and Induction of Immune Protection. J. Virol. 79: 11873-11891 [Abstract] [Full Text]  
  • Aldaz-Carroll, L., Whitbeck, J. C., Ponce de Leon, M., Lou, H., Hirao, L., Isaacs, S. N., Moss, B., Eisenberg, R. J., Cohen, G. H. (2005). Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5R. J. Virol. 79: 6260-6271 [Abstract] [Full Text]  
  • Law, M., Putz, M. M., Smith, G. L. (2005). An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J. Gen. Virol. 86: 991-1000 [Abstract] [Full Text]  
  • Su, H.-P., Garman, S. C., Allison, T. J., Fogg, C., Moss, B., Garboczi, D. N. (2005). The 1.51-A structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc. Natl. Acad. Sci. USA 102: 4240-4245 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»